COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.

Markus WeckmannThomas BahmerJannie Marie SandSarah Rank RønnowMartin PechCornelis Joseph VermeulenAlen FaizDiana Julie LeemingMorten Asser KarsdalLars Peter LundingBrian George G OliverMichael WegmannGudrun Ulrich-MerzenichUwe R JuergensJannis DuhnYves LaumonnierOlga DanovKatherina SewaldUlrich ZisslerMarnix JonkerInke KönigGesine HansenErika Von Mutius Oliver FuchsAnna-Maria DittrichBianca SchaubChristine HappleKlaus F RabeMaarten van de BergeJanette Kay BurgessMatthias Volkmar Koppnull null

Published in: The European respiratory journal (2021)

C4Ma3 levels depend on lung mast cell chymase and are increased in a severe, exacerbating allergic asthma phenotype. C4Ma3 may serve as a novel biomarker to predict anti-IgE therapy response.

Keyphrases

allergic rhinitis
chronic obstructive pulmonary disease
lung function
early onset
cystic fibrosis
mesenchymal stem cells
drug induced